|
DE122007000016I1
(de)
*
|
1991-07-19 |
2007-05-24 |
Univ Queensland |
Impfstoffe gegen Papillomavirus
|
|
DE122007000099I1
(de)
|
1992-06-25 |
2008-03-27 |
|
Papillomavirus vakzine
|
|
US5437951A
(en)
*
|
1992-09-03 |
1995-08-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Self-assembling recombinant papillomavirus capsid proteins
|
|
US5618536A
(en)
*
|
1992-09-03 |
1997-04-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Chimeric papillomavirus-like particles
|
|
US20020164350A1
(en)
|
1992-09-03 |
2002-11-07 |
Lowy Douglas R. |
Chimeric papillomavirus-like particles
|
|
DE69434383T2
(de)
*
|
1993-03-09 |
2005-11-24 |
The University Of Rochester |
Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
|
|
US8062642B1
(en)
|
1993-03-09 |
2011-11-22 |
University Of Rochester |
Production of papillomavirus capsid protein and virus-like particles
|
|
US6153201A
(en)
*
|
1993-03-09 |
2000-11-28 |
University Of Rochester |
Oral immunization with papillomavirus virus-like particles
|
|
GB9306731D0
(en)
*
|
1993-03-31 |
1993-05-26 |
Cancer Res Campaign Tech |
Vaccines
|
|
AU719837B2
(en)
*
|
1993-03-31 |
2000-05-18 |
Cancer Research Campaign Technology Limited |
Pharmaceuticals based on papillomaviruses
|
|
GB9313556D0
(en)
*
|
1993-07-01 |
1993-08-18 |
British Tech Group |
Synthetic peptides of human papillomavirus
|
|
GB2279651A
(en)
*
|
1993-07-01 |
1995-01-11 |
British Tech Group |
Synthetic peptides of human papillomavirus
|
|
AUPM358894A0
(en)
*
|
1994-01-31 |
1994-02-24 |
Csl Limited |
Modified papilloma virus l2 protein and vlps formed therefrom
|
|
DE4415743C2
(de)
*
|
1994-05-04 |
1996-10-10 |
Deutsches Krebsforsch |
Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
|
|
JP3863559B2
(ja)
*
|
1994-05-16 |
2006-12-27 |
メルク エンド カンパニー インコーポレーテッド |
乳頭腫ウィルスワクチン
|
|
US5888516A
(en)
*
|
1994-05-16 |
1999-03-30 |
Merck & Co. Inc. |
Recombinant papillomavirus vaccines
|
|
AUPM566794A0
(en)
*
|
1994-05-17 |
1994-06-09 |
University Of Queensland, The |
Process and product
|
|
IL113817A
(en)
*
|
1994-06-30 |
2001-03-19 |
Merck & Co Inc |
Polynucleotide vaccne for papillomavirus
|
|
AU717647B2
(en)
*
|
1994-10-06 |
2000-03-30 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Chimeric papillomavirus-like particles
|
|
AU717932B2
(en)
*
|
1994-10-06 |
2000-04-06 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Chimeric papillomavirus-like particles
|
|
DE19526752C2
(de)
*
|
1995-07-21 |
1997-08-07 |
Lutz Prof Dr Gissmann |
Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln
|
|
AU2003235191B2
(en)
*
|
1994-10-07 |
2006-09-21 |
Loyola University Of Chicago |
Papilloma virus-like particles, fusion proteins as well as processes for their production
|
|
WO1996011272A2
(de)
*
|
1994-10-07 |
1996-04-18 |
Medigene Gesellschaft Für Molekularbiologische Diagnostik, Theraphie Und Technologie Mbh |
Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
|
|
DE4435907C2
(de)
*
|
1994-10-07 |
1997-07-24 |
Lutz Prof Dr Gissmann |
Papillomavirusähnliche Partikel und deren Anwendung
|
|
AR004464A1
(es)
*
|
1994-11-14 |
1998-12-16 |
Merck Sharp & Dohme |
Un metodo para producir una proteina de capside de papilomavirus
|
|
US5955087A
(en)
*
|
1995-02-24 |
1999-09-21 |
Cantab Pharmaceuticals Research Limited |
Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
|
|
US5840306A
(en)
*
|
1995-03-22 |
1998-11-24 |
Merck & Co., Inc. |
DNA encoding human papillomavirus type 18
|
|
GB9505784D0
(en)
*
|
1995-03-22 |
1995-05-10 |
Lynxvale Ltd |
Anti-tumour treatment
|
|
US5820870A
(en)
*
|
1995-03-22 |
1998-10-13 |
Merck & Co., Inc. |
Recombinant human papillomavirus type 18 vaccine
|
|
IL117459A
(en)
*
|
1995-03-22 |
2005-11-20 |
Merck & Co Inc |
Dna encoding human papillomavirus type 18
|
|
IL117591A0
(en)
*
|
1995-03-30 |
1996-07-23 |
Merck & Co Inc |
Synthetic DNA encoding human papillomavirus type 11 L1 protein
|
|
US5821087A
(en)
*
|
1995-03-30 |
1998-10-13 |
Merck & Co., Inc. |
Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
|
|
SE9501512D0
(sv)
*
|
1995-04-24 |
1995-04-24 |
Euro Diagnostica Ab |
Synthetic peptide-defined eptopes useful for vaccination against papillomavirus
|
|
EP0863982B1
(en)
*
|
1995-11-15 |
2004-01-21 |
Merck & Co., Inc. |
Synthetic hpv11 virus-like particles
|
|
US6908615B1
(en)
|
1996-03-18 |
2005-06-21 |
Merck & Co., Inc. |
DNA encoding human papilloma virus type 18
|
|
FR2749323B1
(fr)
*
|
1996-06-04 |
1998-07-10 |
Pasteur Merieux Serums Vacc |
Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
|
|
FR2751879B1
(fr)
*
|
1996-07-30 |
1998-10-30 |
Transgene Sa |
Composition pharmaceutique contre les tumeurs et infections a papillomavirus
|
|
US7118754B1
(en)
|
1996-07-30 |
2006-10-10 |
Transgene S.A. |
Pharmaceutical composition for treating papillomavirus tumors and infection
|
|
WO1998014564A1
(en)
*
|
1996-10-04 |
1998-04-09 |
Merck & Co., Inc. |
Synthetic hpv16 virus-like particles
|
|
GB9621091D0
(en)
|
1996-10-09 |
1996-11-27 |
Fondation Pour Le Perfectionem |
Attenuated microorganisms strains and their uses
|
|
EP0948351B1
(en)
*
|
1996-12-09 |
2004-02-25 |
Merck & Co., Inc. |
Synthetic hpv16 virus-like particles
|
|
ATE341339T1
(de)
*
|
1996-12-20 |
2006-10-15 |
Merck & Co Inc |
Zusammensetzungen von rekombinanten papillomavirus vakzinen
|
|
EP0980257A1
(en)
*
|
1997-05-01 |
2000-02-23 |
Chiron Corporation |
Use of virus-like particles as adjuvants
|
|
AU755679B2
(en)
*
|
1997-07-03 |
2002-12-19 |
Medimmune, Llc |
Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture,and the use thereof as diagnostic, prophylactic or therapy
|
|
FR2766091A1
(fr)
|
1997-07-18 |
1999-01-22 |
Transgene Sa |
Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
|
|
US6962777B1
(en)
*
|
1997-09-05 |
2005-11-08 |
Medimmune, Inc. |
In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
|
|
US6228368B1
(en)
|
1997-10-06 |
2001-05-08 |
Loyola University Of Chicago |
Papilloma virus capsomere formulations and method of use
|
|
US7182947B2
(en)
|
1998-02-20 |
2007-02-27 |
Medigene Ag |
Papillomavirus truncated L1 protein and fusion protein constructs
|
|
US7494658B2
(en)
|
1998-02-20 |
2009-02-24 |
Medigene Ag |
Papilloma virus truncated L1 protein and fusion protein constructs
|
|
US20020039584A1
(en)
|
1998-02-20 |
2002-04-04 |
Medigene Ag |
Papilloma virus capsomere vaccine formulations and methods of use
|
|
CA2229955C
(en)
|
1998-02-20 |
2003-12-09 |
Medigene Gmbh |
Papilloma virus capsomere vaccine formulations and methods of use
|
|
US6926897B1
(en)
|
1998-03-24 |
2005-08-09 |
Medigene Aktiengesellschaft |
Medicament for the avoidance or treatment of papillomavirus-specific tumour
|
|
US6692752B1
(en)
|
1999-09-08 |
2004-02-17 |
Smithkline Beecham Biologicals S.A. |
Methods of treating human females susceptible to HSV infection
|
|
AUPP765398A0
(en)
|
1998-12-11 |
1999-01-14 |
University Of Queensland, The |
Treatment of papillomavirus infections
|
|
DE19925234A1
(de)
*
|
1999-06-01 |
2000-12-14 |
Medigene Ag |
Capsomere, stabile Capsomere, Capside, VLPs, oder CVLPs bzw. damit beladenen Zellen und ihre Verwendung in Diagnostik und Therapie
|
|
DE19925199A1
(de)
*
|
1999-06-01 |
2000-12-07 |
Medigene Ag |
Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
|
|
DE19925235A1
(de)
*
|
1999-06-01 |
2000-12-07 |
Medigene Ag |
Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
|
|
GB9921146D0
(en)
*
|
1999-09-07 |
1999-11-10 |
Smithkline Beecham Biolog |
Novel composition
|
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
AUPR446801A0
(en)
|
2001-04-18 |
2001-05-17 |
University Of Queensland, The |
Novel compositions and uses therefor
|
|
KR100785397B1
(ko)
|
2001-06-28 |
2007-12-13 |
아피메즈 주식회사 |
인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신
|
|
DE10137102A1
(de)
|
2001-07-30 |
2003-02-27 |
Deutsches Krebsforsch |
Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
|
|
AU2002367977B2
(en)
|
2001-08-13 |
2008-06-19 |
University Of Rochester |
Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
|
|
US20050118139A1
(en)
*
|
2001-08-23 |
2005-06-02 |
Lingyi Huang |
Vaccine using papilloma virus e proteins delivered by viral vector
|
|
KR20030067873A
(ko)
*
|
2002-02-08 |
2003-08-19 |
주식회사 유니크 |
솔레노이드 밸브
|
|
GB0206360D0
(en)
|
2002-03-18 |
2002-05-01 |
Glaxosmithkline Biolog Sa |
Viral antigens
|
|
DK1648931T3
(da)
|
2003-07-21 |
2011-03-07 |
Transgene Sa |
Multifunktionelle cytokiner
|
|
WO2005030041A2
(en)
|
2003-09-25 |
2005-04-07 |
Third Wave Technologies, Inc. |
Detection of hpv
|
|
ATE474596T1
(de)
*
|
2004-09-10 |
2010-08-15 |
Asahi Glass Co Ltd |
Impfstoff gegen humanes papillomavirus zur oralen verabreichung
|
|
US8021992B2
(en)
*
|
2005-09-01 |
2011-09-20 |
Taiwan Semiconductor Manufacturing Co., Ltd. |
High aspect ratio gap fill application using high density plasma chemical vapor deposition
|
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
|
US8080643B2
(en)
*
|
2006-09-05 |
2011-12-20 |
Third Wave Technologies, Inc. |
HPV primers
|
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
|
PT2468300T
(pt)
|
2006-09-26 |
2018-01-30 |
Infectious Disease Res Inst |
Composição para vacina contendo adjuvante sintético
|
|
EP2426142A3
(en)
|
2006-10-16 |
2012-06-13 |
Genelux Corporation |
Modified vaccinia virus strains for use in a diagnostic and therapeutic method
|
|
HRP20161606T1
(hr)
|
2007-03-02 |
2017-01-13 |
Glaxosmithkline Biologicals Sa |
Novi postupak i pripravci
|
|
CN101835797A
(zh)
*
|
2007-11-23 |
2010-09-15 |
上海泽润生物科技有限公司 |
人乳头状瘤病毒主要衣壳蛋白l1基因及其用途
|
|
US20100285056A1
(en)
*
|
2008-01-09 |
2010-11-11 |
Konkuk University Industrial Cooperation Corp. |
Baculovirus-Based Vaccines
|
|
CN102099053A
(zh)
|
2008-05-26 |
2011-06-15 |
卡迪拉保健有限公司 |
麻疹-人乳头瘤组合疫苗
|
|
GB0815872D0
(en)
|
2008-09-01 |
2008-10-08 |
Pasteur Institut |
Novel method and compositions
|
|
GB0820822D0
(en)
|
2008-11-13 |
2008-12-24 |
Inst Catala D Oncologia |
Novel product and processes
|
|
US20120115207A1
(en)
*
|
2009-04-03 |
2012-05-10 |
Deutsches Krebsforschungszentrum |
Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
|
|
CN102481312B
(zh)
|
2009-06-05 |
2015-07-15 |
传染性疾病研究院 |
合成的吡喃葡萄糖脂佐剂
|
|
US9566323B2
(en)
|
2009-06-19 |
2017-02-14 |
Eyegene Inc. |
Vaccine for cervical cancer
|
|
WO2011026111A1
(en)
|
2009-08-31 |
2011-03-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Oral delivery of a vaccine to the large intestine to induce mucosal immunity
|
|
AU2011237393B2
(en)
|
2010-04-08 |
2015-01-22 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
B-cell antigen presenting cell assay
|
|
JP6153866B2
(ja)
|
2010-05-25 |
2017-06-28 |
キアゲン ガイサーズバーグ アイエヌシー． |
迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ
|
|
KR101349291B1
(ko)
|
2010-08-10 |
2014-01-10 |
한국생명공학연구원 |
고초균을 이용하여 자궁경부암 백신을 제조하는 방법
|
|
WO2012141984A1
(en)
|
2011-04-08 |
2012-10-18 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
PL2811981T3
(pl)
|
2012-02-07 |
2019-09-30 |
Infectious Disease Research Institute |
Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
|
|
WO2013139744A1
(en)
|
2012-03-18 |
2013-09-26 |
Glaxosmithkline Biologicals S.A. |
Method of vaccination against human papillomavirus
|
|
KR102136433B1
(ko)
|
2012-05-16 |
2020-07-22 |
이뮨 디자인 코포레이션 |
Hsv-2 백신
|
|
JP6430949B2
(ja)
|
2012-10-23 |
2018-11-28 |
エモリー ユニバーシティ |
Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
|
|
EP2986303B1
(en)
|
2013-04-18 |
2020-02-26 |
Immune Design Corp. |
Gla monotherapy for use in cancer treatment
|
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
|
IL310015B2
(en)
|
2013-12-31 |
2026-02-01 |
Access To Advanced Health Inst |
Single vial formulation
|
|
US10314906B2
(en)
|
2015-03-18 |
2019-06-11 |
University Of Massachusetts |
Virus-like particle compositions and vaccines against Epstein-Barr virus infection and disease
|
|
KR101908438B1
(ko)
*
|
2016-02-05 |
2018-10-16 |
(주)피앤피바이오팜 |
Arsntd를 융합파트너로 이용한 수용성 및 활성형 재조합단백질의 생산방법 및 그 생산물
|
|
BR112018017141A2
(pt)
|
2016-02-22 |
2019-01-02 |
Boehringer Ingelheim Vetmedica Gmbh |
método para a imobilização de biomoléculas
|
|
DK3458475T3
(da)
|
2016-05-16 |
2022-09-12 |
Access To Advanced Health Inst |
Formulering, der indeholder tlr-agonist, og anvendelsesfremgangsmåder
|
|
US11266602B2
(en)
|
2016-05-16 |
2022-03-08 |
Infectious Disease Research Institute |
PEGylated liposomes and methods of use
|
|
AU2017273650B2
(en)
|
2016-06-01 |
2022-08-18 |
Access To Advanced Health Institute |
Nanoalum particles containing a sizing agent
|
|
JP2020524143A
(ja)
|
2017-06-15 |
2020-08-13 |
インフェクシャス ディズィーズ リサーチ インスティチュート |
ナノ構造脂質担体、安定エマルジョン、およびその使用
|
|
CA3078223A1
(en)
|
2017-09-08 |
2019-03-14 |
Infectious Disease Research Institute |
Liposomal formulations comprising saponin and methods of use
|
|
RU2681174C1
(ru)
*
|
2018-07-12 |
2019-03-04 |
Закрытое акционерное общество научно-производственная компания "Комбиотех" |
Способ получения рекомбинантной вакцины для профилактики папилломавирусной инфекции человека, рекомбинантная вакцина
|
|
EP3976092A1
(en)
|
2019-05-25 |
2022-04-06 |
Infectious Disease Research Institute |
Composition and method for spray drying an adjuvant vaccine emulsion
|
|
JP7017811B2
(ja)
*
|
2020-02-13 |
2022-02-09 |
国立研究開発法人農業・食品産業技術総合研究機構 |
ウイルス様粒子及びその使用
|
|
AU2021337493A1
(en)
|
2020-09-04 |
2023-05-18 |
Access To Advanced Health Institute |
Co-lyophilized rna and nanostructured lipid carrier
|
|
JP2024506364A
(ja)
|
2021-02-11 |
2024-02-13 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Ｈｐｖワクチンの製造
|
|
EP4457774A1
(fr)
*
|
2021-12-29 |
2024-11-06 |
Hitachi High-Tech Corporation |
Methode d'analyse d'images de microbes
|
|
EP4583841A1
(en)
|
2022-09-09 |
2025-07-16 |
Access to Advanced Health Institute |
Immunogenic vaccine composition incorporating a saponin
|